Why the study?
Does serial measurement of respiratory sinus arrhythmia amplitude predict doxorubicin-induced congestive heart failure better than radionuclide ejection fraction in cancer patients?
Does serial measurement of respiratory sinus arrhythmia amplitude predict doxorubicin-induced congestive heart failure better than radionuclide ejection fraction in cancer patients?
A decline in respiratory sinus arrhythmia amplitude is a specific predictor of doxorubicin-induced congestive heart failure, often occurring months before clinical symptoms.
No takes yet. Share an insight, caveat, or question.
RSA decline may flag doxorubicin cardiotoxicity risk; hypothesis-generating and should not yet alter ejection fraction monitoring.
Hrushesky et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: